On Sunday, Oct. 2, Immunomic Therapeutics Inc.’s scientist, Dr. Franco Pissani, will offer an oral presentation during the International Society for Vaccines’ Annual Congress. The presentation will examine how the LAMP-Vax™ platform technology was applied in the formulation and testing of a peanut allergy mouse model and DNA vaccine coding for sequences of peanut allergens and LAMP-Vax.
Who: Dr. Franco Pissani, Immunomic Therapeutics, Inc. Scientist
What: Oral presentation on recent allergy vaccine findings, open to conference attendees and media
When: Oct. 2, 3 pm EST
Where: Mechanisms of Immune Efficacy SessionatTheBoston Marriot Long Wharf at 296 State St, Boston, MA 02109
Immunomic Therapeutics, Inc. is a privately-held, clinical stage biotech company on a mission to pioneer vaccines that transform lives. The company, based in Rockville, MD, is developing a new generation of nucleic acid vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) Technology. Termed LAMP-Vax™, the exclusive technology works with the body’s natural biochemistry system and has the potential to improve a broad range of vaccines. Immunomic Therapeutics successfully licensed their allergy platform to Astellas Pharma in 2015 and is now focused on cancer immunotherapy. The LAMP platform has been tested in Phase I and II clinical studies. For more information, please visit www.immunomix.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005896/en/Business Wire
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.